Suzhou Smart Nuclide Pharmaceutical Technology Company was founded in 2015, our aim is to provide innovative diagnostic and therapeutic radiopharmaceuticals for patients around the world. Our products focus on thyroid cancer, precision radioactive imaging and targeted radioligand therapy. Since its foundation, Smart Nuclide has raised over 200 million yuan with four rounds of venture capital investment.
In Smart Nuclide, we build several technology platforms focusing on the discovery, R&D, and production of radiopharmaceuticals based on single-domain antibody, with independent intellectual property rights. Based on our proprietary technology platforms, we have prospectively formed a robust and competitive portfolio of pipelines with more than 10 innovative radioactive diagnostic and therapeutic products.
MORE
Innovation & Scientific Excellence
Pioneering Four Integrated Platform Technologies Combining Nanobodies and Radionuclide Labeling
Investors
Partners
Since its establishment, Smart Nuclide has consistently adhered to an innovative philosophy, strengthening collaboration with domestic and international universities, research institutes, and medical institutions. This commitment aims to provide patients with higher-quality nuclear medicine treatment solutions. To date, We have established cooperative partnerships with multiple organizations.
